BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

843 related articles for article (PubMed ID: 25875173)

  • 1. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study.
    Senetta R; Duregon E; Sonetto C; Spadi R; Mistrangelo M; Racca P; Chiusa L; Munoz FH; Ricardi U; Arezzo A; Cassenti A; Castellano I; Papotti M; Morino M; Risio M; Cassoni P
    PLoS One; 2015; 10(4):e0123759. PubMed ID: 25875173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.
    Machackova T; Trachtova K; Prochazka V; Grolich T; Farkasova M; Fiala L; Sefr R; Kiss I; Skrovina M; Dosoudil M; Berindan-Neagoe I; Svoboda M; Slaby O; Kala Z
    Cancer Genomics Proteomics; 2020; 17(3):249-257. PubMed ID: 32345666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.
    Abdul-Jalil KI; Sheehan KM; Kehoe J; Cummins R; O'Grady A; McNamara DA; Deasy J; Breathnach O; Grogan L; O'Neill BD; Faul C; Parker I; Kay EW; Hennessy BT; Gillen P
    Colorectal Dis; 2014 Jan; 16(1):O16-25. PubMed ID: 24119076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.
    Garcia-Aguilar J; Chen Z; Smith DD; Li W; Madoff RD; Cataldo P; Marcet J; Pastor C
    Ann Surg; 2011 Sep; 254(3):486-92; discussion 492-3. PubMed ID: 21865946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer.
    Yu J; Li N; Wang X; Ren H; Wang W; Wang S; Song Y; Liu Y; Li Y; Zhou X; Luo A; Liu Z; Jin J
    Oncotarget; 2016 Sep; 7(39):64233-64243. PubMed ID: 27572313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
    Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
    Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of sequential endorectal US to predict the tumor response of preoperative chemoradiotherapy in rectal cancer.
    Li N; Dou L; Zhang Y; Jin J; Wang G; Xiao Q; Li Y; Wang X; Ren H; Fang H; Wang W; Wang S; Liu Y; Song Y
    Gastrointest Endosc; 2017 Mar; 85(3):669-674. PubMed ID: 27354104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study.
    Hosseini S; Nguyen N; Mohammadianpanah M; Mirzaei S; Bananzadeh AM
    J Gastrointest Cancer; 2019 Dec; 50(4):716-722. PubMed ID: 29984382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Predictors of Response to Neoadjuvant Chemoradiation for Rectal Cancer.
    Kundel Y; Nasser NJ; Rath-Wolfson L; Purim O; Yanichkin N; Brenner R; Zehavi T; Nardi Y; Fenig E; Sulkes A; Brenner B
    Am J Clin Oncol; 2018 Jun; 41(6):613-618. PubMed ID: 27740975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
    Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
    J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Matsushita K; Kawamura M; Okugawa Y; Hiro J; Inoue Y; Uchida K; Mohri Y; Kusunoki M
    Oncol Rep; 2012 Sep; 28(3):855-61. PubMed ID: 22711167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
    Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
    Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.
    Russo AL; Ryan DP; Borger DR; Wo JY; Szymonifka J; Liang WY; Kwak EL; Blaszkowsky LS; Clark JW; Allen JN; Zhu AX; Berger DL; Cusack JC; Mamon HJ; Haigis KM; Hong TS
    J Gastrointest Cancer; 2014 Mar; 45(1):34-9. PubMed ID: 24006244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of diffusion-weighted MRI and apparent diffusion coefficient measurements for predicting the response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy.
    Iannicelli E; Di Pietropaolo M; Pilozzi E; Osti MF; Valentino M; Masoni L; Ferri M
    Abdom Radiol (NY); 2016 Oct; 41(10):1906-17. PubMed ID: 27323759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation.
    Carpinetti P; Donnard E; Bettoni F; Asprino P; Koyama F; Rozanski A; Sabbaga J; Habr-Gama A; Parmigiani RB; Galante PA; Perez RO; Camargo AA
    Oncotarget; 2015 Nov; 6(35):38360-71. PubMed ID: 26451609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
    Edden Y; Wexner SD; Berho M
    Colorectal Dis; 2012 May; 14(5):555-61. PubMed ID: 21689364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients.
    Lopes-Ramos CM; Habr-Gama A; Quevedo Bde S; FelĂ­cio NM; Bettoni F; Koyama FC; Asprino PF; Galante PA; Gama-Rodrigues J; Camargo AA; Perez RO; Parmigiani RB
    BMC Med Genomics; 2014 Dec; 7():68. PubMed ID: 25496125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Della Vittoria Scarpati G; Falcetta F; Carlomagno C; Ubezio P; Marchini S; De Stefano A; Singh VK; D'Incalci M; De Placido S; Pepe S
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1113-9. PubMed ID: 22172905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer?
    Perez RO; Habr-Gama A; Pereira GV; Lynn PB; Alves PA; Proscurshim I; Rawet V; Gama-Rodrigues J
    Colorectal Dis; 2012 Jun; 14(6):714-20. PubMed ID: 22568644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation in BRAF and SMAD4 associated with resistance to neoadjuvant chemoradiation therapy in locally advanced rectal cancer.
    Jiang D; Wang X; Wang Y; Philips D; Meng W; Xiong M; Zhao J; Sun L; He D; Li K
    Virchows Arch; 2019 Jul; 475(1):39-47. PubMed ID: 31056731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.